Episurf Medical AB Class B · OMXSTO:EPIS_B
Episurf Medical AB Class B — Shareholder Meeting (June 2016)
14 slides from Episurf Medical AB Class B's shareholder meeting presentation, Jun 8, 2016
Slide 1: The Journey to Mainstream
The Journey to Mainstream Rosemary Cunningham Thomas, CEO Serendipity Ixora AGM 8 June 2016
Slide 2: Michael Wohlgehage
Michael Wohlgehage Age 49 Lill
Slide 3: Surgeries
DeEPIsURE Medical Surgeries
Slide 4: Slide 4
Slide 5: Patients > 1 year, > 2 years, > 3 years
47/15/4 Patients > 1 year Patients > 2 years Patients > 3 years 5
Slide 6: Revision rate
DeEPIsURE Medical
Slide 7: …with clinical results now presented…
…with clinical results now presented… • Clinical results now presented at two key ”SURVIVAL”1 ”SURVIVAL”2 knee specialists meetings 100% 100% • In total, we now have 1 year data on 24 patients FKA • Results show; 75% 73% – Correct implant positioning – Joint space preserved – No adverse events – Sig
Slide 8: Episurf Medical's goals and objectives
Episurf Medical’s goals and objectives are to mainstream patient-specific treatment options as a new standard within the orthopaedic industry Our ambition is to achieve 10% market penetration of the treatment market for Grade III-IV cartilage lesions 8
Slide 9: The treatment options and the players
The treatment options and the players Individuals suffering from knee joint injuries are referred to one of several existing treatment methods, however all suffering from one or several weaknesses or limitations Existing treatment methods based o Often referred to non- Highly invasive and – The join
Slide 10: Advancing on the Technology Adoption Curve
Advancing on the Technology Adoption Curve What we achieve during the early adoption phase will give us access to 85% of the remaining market Innovators Early adopters Early majority Late Majority Laggards 2,5% 13,5% 34% 34% 16% Episurf Medical is exactly at First sales people started û the correct
Slide 11: Clinical Advisory Board
Clinical Advisory Board Episurf has an active KOL-strategy, and in 2015 the company formed an experienced and international Clinical Advisory Board Leif Ryd, Associate Johannes Holz, Karl Eriksson, Tim Spalding, Seppo Koskinen, Mats Brittberg, Professor Dr Med Associate Associate Professor Professor
Slide 12: A global strategy
A global strategy Episurf is currently executing its European commercialization strategy while also preparing a US entry strategy The US Europe • Regulatory analysis pending • 100 implants across Europe • 510(k) vs PMA • Direct sales force focusing on Germany, the UK, Belgium and the Nordics • Marke
Slide 13: 2016 Strategic Initiatives
2016 Strategic Initiatives » Consistent commercial execution » Continued product and service innovation via our proprietary technology platform » Producing scientifically robust clinical evidence » Pursue the relevant regulatory and reimbursement pathways to support geographical expansion including
Slide 14: Thank you!
Thank you! The future The status quo 14